Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20699031 | 0.86 | NLRP3 (0.34) | NLRP3AKR1B1PTGDR2 | |
| SCHEMBL30791038 | 0.85 | NLRP3 (0.35) | NLRP3AKR1B1RXRARXRBRXRG | |
| SCHEMBL20681231 | 0.85 | NLRP3 (0.35) | NLRP3AKR1B1RXRARXRBRXRG | |
| SCHEMBL20699030 | 0.84 | NLRP3 (0.36) | NLRP3GCGR | |
| SCHEMBL29687458 | 0.81 | NLRP3 (0.48) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL20681566 | 0.81 | NLRP3 (0.48) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL23319794 | 0.78 | NLRP3 (0.36) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL25139065 | 0.77 | NLRP3 (0.43) | NLRP3RXRARXRBRXRGPTGDR2 | |
| SCHEMBL20698952 | 0.76 | NLRP3 (0.35) | NLRP3 | |
| SCHEMBL25139131 | 0.75 | NLRP3 (0.34) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |